Braeburn focuses on advancing next-generation therapies for opioid use disorder, with personalized dosing regimens and delivery options. They aim to reduce stigma and raise awareness about opioid use disorder as a chronic brain disease that can be effectively treated with evidence-based medication. Braeburn is known for their highly effective organization and their commitment to collaboration and execution in their mission to fight the opioid epidemic. They are currently developing long-acting implantable and injectable therapies, including their FDA-approved product Probufine for opioid dependence and CAM2038, which is in the process of refilling the New Drug Application for opioid dependence and is in phase 3 for pain management. CAM2038 is a long-acting formulation delivered subcutaneously using a proprietary system called FluidCrystal.